A clinical trial update for ecnoglutide, also known as XW003, was recorded on August 28, 2026. The study, registered as NCT07387094, is titled "A Study of XW003 in Obese Participants With Obstructive Sleep Apnea But Not Receive Positive Airway Pressure Therapy." It is listed as a Phase 3 trial and its current status is recruiting.
The trial focuses on obese participants who have obstructive sleep apnea and are not undergoing positive airway pressure therapy. Ecnoglutide remains classified as an unapproved compound under research investigation. No outcome data, efficacy findings, or safety results have been reported for this trial at this stage.
This update reflects only the trial's registration status and recruitment phase as of the listed date. No conclusions about the compound's effects in this population can be drawn from a recruiting status alone. Further updates would be expected as the trial progresses through enrollment and subsequent phases.
Readers interested in background on this compound can consult the ecnoglutide overview for additional context.